Posted 9/9/2015 1:24 PM (GMT 0)
Merely having antibodies doesn't mean you have to switch medications, especially if remicade/inflixamab is currently working well for you. Often the dosage and/or frequency can be increased to counter act antibodies (up to a maximum of 10mgs per kilogram every 4 weeks).
If you've developed antibodies to one anti-tnf treatment (that is remicade/inflixamab) then you can still try other anti-tnf treatments (such as humira/adalimumab or simponi/golimumab) and not necessarily end up developing antibodies to them. The reason you developed antibodies to remicade/inflixamab is it is part mouse protein, your immune system recognized it as a foreign invader, and developed antibodies to stop that perceived threat. Although humira/adalimumab and simponi/golimumab are still anti-tnf treatments, they are fully humanized proteins and are therefore less likely to cause the development of antibodies then remicade is. I mention this primarily so you know you do have additional treatment options beyond just entvyio/Vedolizumab, and most anti-tnf treatments are much, much quicker acting than entvyio/Vedolizumab is. Not to completely knock entvyio/Vedolizumab, which has worked for some. Rather, to let you know what's available for you.